跳至主要内容
临床试验/NCT05604794
NCT05604794已完成4 期

Retrospective Review of Ketamine Assisted Psychotherapy Program on Mental Health at Field Trip Health Centres in North America

Field Trip Health21 个研究点 分布在 2 个国家目标入组 1,806 人开始时间: 2020年3月13日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,806
试验地点
21
主要终点
6-item PTSD Checklist (PCL-6)

研究概览

简要总结

Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post traumatic stress, that would be detectable up to 6 months after treatment. The results of this study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.

详细描述

Background: Ketamine-Assisted Psychotherapy (KAP) has shown positive effects within clinical trial settings and over short-term follow-ups, but sustained effects in real-world treatment settings remain unclear. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health issues. We hypothesized that there would be significant reductions in psychological distress over time.

Objective: To examine treatment effects at 1, 3, and 6 months relative to baseline on depression, anxiety, and post traumatic stress outcomes.

Design: A retrospective intervention-only effectiveness trial.

Setting: KAP was administered across 11 Field Trip Health clinics in North America. Intervention: KAP consisting of 4-6 guided ketamine sessions with psychotherapy-only visits after dose 1 and 2 and then after every 2 subsequent doses.

Outcomes: Self-reported measures of symptoms of depression, anxiety, and post traumatic stress at 1, 3, and 6 months.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Written informed consent
  • Over the age of 18
  • Should be psychologically and medically cleared by a psychiatrist, family physician, or treatment team
  • Diagnosed with Major Depressive Disorder (MDD), Bipolar Depression, Generalized Anxiety Disorder, Obsessive Compulsive Disorder (OCD), and Eating Disorder by a licensed healthcare practitioner (including Field Trip Consultants)
  • A significant history of trauma and/or formal diagnosis of PTSD as per the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)
  • Individuals who have received Electroconvulsive Therapy (ECT) or other neuromodulatory treatments like Transcranial Magnetic Stimulation (TMS)
  • Individuals reporting suicidal ideation may be included, as suicidal ideation is a symptom of a Major Depressive Episode (MDE)

排除标准

  • Individuals who are unable to consent to the treatment
  • Pregnant women and nursing mothers
  • -Note that Post Partum Depression (PPD) can be considered on a case-by-case basis in consultation with the National Medical Director.
  • There is a relative (not absolute) contraindication for individuals with a Body Mass Index (BMI) of above
  • These clients must be given thorough consideration by the medical team.
  • Any individual who has met DSM 5 criteria for a Substance Use Disorder in the past 3 months.
  • Note that patients with alcohol, opioid, benzodiazepine, cocaine, and amphetamine use disorders need to go through detox (for alcohol/benzodiazepines) and be sober for 4 weeks.
  • Note that mild active alcohol, cocaine, and cannabis use can be considered on a case-by-case basis at the comfort level of the treatment team if the client has demonstrated abstaining or significant reduction of use prior to starting treatment.
  • Daily use of moderate to high doses of benzodiazepines
  • Individuals who are experiencing psychotic symptoms as part of an MDE (mood congruent/ mood incongruent)
  • Psychosis: Schizophrenia, Schizoaffective disorder, Bipolar 1 with psychotic features during mania
  • Active Mania: Bipolar 1 (chronic non-disruptive hypomania is an exception at the discretion of the consultant)
  • Borderline Personality Disorder
  • Uncontrolled medical disorders
  • Physical conditions with negative interaction with ketamine (e.g., metabolic blood disorder)
  • Individuals with symptomatic acute brain injury within 90 days of serious injury
  • Individuals diagnosed with moderate to severe sleep apnea
  • Individuals who are unable to identify a person or service to assure their safe transport to home post treatment

研究组 & 干预措施

Clients

Experimental

Adult patients coping with symptoms of depression, anxiety, and post traumatic stress

干预措施: Ketamine-Assisted Psychotherapy (KAP) (Combination Product)

结局指标

主要结局

6-item PTSD Checklist (PCL-6)

时间窗: Change from 3 months compared to baseline

Self-reported measure of post traumatic stress, ranging from 6-30. Higher scores are worse.

9-item Patient Health Questionnaire (PHQ-9)

时间窗: Change from 3 months compared to baseline

Self-reported measure of depression, ranging from 0-27. Higher scores are worse.

7-item Generalized Anxiety Disorder Measure (GAD-7)

时间窗: Change from 3 months compared to baseline

Self-reported measure of anxiety, ranging from 0-21. Higher scores are worse.

次要结局

  • 9-item Patient Health Questionnaire (PHQ-9)(Change from 6 months compared to baseline)
  • 7-item Generalized Anxiety Disorder Measure (GAD-7)(Change from 6 months compared to baseline)
  • 6-item PTSD Checklist (PCL-6)(Change from 6 months compared to baseline)

研究者

发起方
Field Trip Health
申办方类型
Industry
责任方
Sponsor

研究点 (21)

Loading locations...

相似试验